gw1zji58

Property	Value
?:abstract	Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 receptor, holds the potential for treating coronavirus disease 2019 (COVID-19) patients, particularly those at high risk of cytokine storm syndrome However, data regarding the clinical impact of treatment with TCZ in patients with COVID-19 are limited This study was conducted to evaluate the safety and effectiveness of TCZ as an adjunct therapy for the treatment of severe COVID-19 infection This was a retrospective observational chart review of confirmed COVID-19 patients who received TCZ, along with other COVID-19 therapies The outcomes of interest included changes in vital signs such as temperature and laboratory biomarkers, duration of mechanical ventilation, adverse events possibly associated with TCZ, and intensive care unit and hospital lengths of stay This study included 38 patients with an average age of 63 years (IQR, 48-70 years) The average dose of TCZ given was 519 +/- 61 mg Median C-reactive protein significantly decreased following TCZ administration (189 9 vs 54 8 mg/L, P = 003) Nineteen of all febrile patients before the initiation of TCZ (73%) became fever free on the fourth day of TCZ treatment Following TCZ treatment, 11 patients developed infections because of multidrug-resistant bacteria, and elevated liver transaminases were observed in 6 patients The preliminary findings of this study suggested TCZ appeared to ameliorate COVID-19-related cytokine storm syndrome However, large randomized, controlled trials are needed to investigate whether treatment with TCZ is associated with better outcomes in COVID-19 Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 receptor, holds the potential for treating coronavirus disease 2019 (COVID-19) patients, particularly those at high risk of cytokine storm syndrome. However, data regarding the clinical impact of treatment with TCZ in patients with COVID-19 are limited. This study was conducted to evaluate the safety and effectiveness of TCZ as an adjunct therapy for the treatment of severe COVID-19 infection. This was a retrospective observational chart review of confirmed COVID-19 patients who received TCZ, along with other COVID-19 therapies. The outcomes of interest included changes in vital signs such as temperature and laboratory biomarkers, duration of mechanical ventilation, adverse events possibly associated with TCZ, and intensive care unit and hospital lengths of stay. This study included 38 patients with an average age of 63 years (IQR, 48-70 years). The average dose of TCZ given was 519 ± 61 mg. Median C-reactive protein significantly decreased following TCZ administration (189.9 vs 54.8 mg/L, P = .003). Nineteen of all febrile patients before the initiation of TCZ (73%) became fever free on the fourth day of TCZ treatment. Following TCZ treatment, 11 patients developed infections because of multidrug-resistant bacteria, and elevated liver transaminases were observed in 6 patients. The preliminary findings of this study suggested TCZ appeared to ameliorate COVID-19-related cytokine storm syndrome. However, large randomized, controlled trials are needed to investigate whether treatment with TCZ is associated with better outcomes in COVID-19.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/gw1zji58_hasAnnotation_C0015967> <https://research.tib.eu/covid-19/entity/gw1zji58_hasAnnotation_C0877248> <https://research.tib.eu/covid-19/entity/gw1zji58_hasAnnotation_C1825598> <https://research.tib.eu/covid-19/entity/gw1zji58_hasAnnotation_C3714514>
?:creator	<https://research.tib.eu/covid-19/entity/Mo%2C_Y.%3B_Adarkwah%2C_O.%3B_Zeibeq%2C_J.%3B_Pinelis%2C_E.%3B_Orsini%2C_J.%3B_Gasperino%2C_J.> <https://research.tib.eu/covid-19/entity/Mo%2C_Yoonsun%3B_Adarkwah%2C_Obed%3B_Zeibeq%2C_John%3B_Pinelis%2C_Evgeny%3B_Orsini%2C_Jose%3B_Gasperino%2C_James>
?:journal	J._clin._pharmacol Journal_of_Clinical_Pharmacology
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/gw1zji58_HAS_C0877248_ASSOCIATED_WITH_C1609165> <https://research.tib.eu/covid-19/entity/gw1zji58_HAS_C1609165_ASSOCIATED_WITH_C5203670> <https://research.tib.eu/covid-19/entity/gw1zji58_HAS_C1609165_TREATS_C0015967> <https://research.tib.eu/covid-19/entity/gw1zji58_HAS_C1609165_TREATS_C0948245> <https://research.tib.eu/covid-19/entity/gw1zji58_HAS_C2985546_INTERACTS_WITH_C0063717>
?:source	WHO
?:title	Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1064372 #919841
?:year	2020 2021

Property

Value

?:abstract

Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 receptor, holds the potential for treating coronavirus disease 2019 (COVID-19) patients, particularly those at high risk of cytokine storm syndrome However, data regarding the clinical impact of treatment with TCZ in patients with COVID-19 are limited This study was conducted to evaluate the safety and effectiveness of TCZ as an adjunct therapy for the treatment of severe COVID-19 infection This was a retrospective observational chart review of confirmed COVID-19 patients who received TCZ, along with other COVID-19 therapies The outcomes of interest included changes in vital signs such as temperature and laboratory biomarkers, duration of mechanical ventilation, adverse events possibly associated with TCZ, and intensive care unit and hospital lengths of stay This study included 38 patients with an average age of 63 years (IQR, 48-70 years) The average dose of TCZ given was 519 +/- 61 mg Median C-reactive protein significantly decreased following TCZ administration (189 9 vs 54 8 mg/L, P = 003) Nineteen of all febrile patients before the initiation of TCZ (73%) became fever free on the fourth day of TCZ treatment Following TCZ treatment, 11 patients developed infections because of multidrug-resistant bacteria, and elevated liver transaminases were observed in 6 patients The preliminary findings of this study suggested TCZ appeared to ameliorate COVID-19-related cytokine storm syndrome However, large randomized, controlled trials are needed to investigate whether treatment with TCZ is associated with better outcomes in COVID-19
Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 receptor, holds the potential for treating coronavirus disease 2019 (COVID-19) patients, particularly those at high risk of cytokine storm syndrome. However, data regarding the clinical impact of treatment with TCZ in patients with COVID-19 are limited. This study was conducted to evaluate the safety and effectiveness of TCZ as an adjunct therapy for the treatment of severe COVID-19 infection. This was a retrospective observational chart review of confirmed COVID-19 patients who received TCZ, along with other COVID-19 therapies. The outcomes of interest included changes in vital signs such as temperature and laboratory biomarkers, duration of mechanical ventilation, adverse events possibly associated with TCZ, and intensive care unit and hospital lengths of stay. This study included 38 patients with an average age of 63 years (IQR, 48-70 years). The average dose of TCZ given was 519 ± 61 mg. Median C-reactive protein significantly decreased following TCZ administration (189.9 vs 54.8 mg/L, P = .003). Nineteen of all febrile patients before the initiation of TCZ (73%) became fever free on the fourth day of TCZ treatment. Following TCZ treatment, 11 patients developed infections because of multidrug-resistant bacteria, and elevated liver transaminases were observed in 6 patients. The preliminary findings of this study suggested TCZ appeared to ameliorate COVID-19-related cytokine storm syndrome. However, large randomized, controlled trials are needed to investigate whether treatment with TCZ is associated with better outcomes in COVID-19.

is ?:annotates of